Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Craneware ( (GB:CRW) ) has shared an announcement.
Craneware reported unaudited interim results for the six months to 31 December 2025 showing solid top-line growth and stronger profitability, with revenue up 6% to $105.7m and double-digit increases in adjusted EBITDA, profit before tax and EPS. Annual recurring revenue rose 4% to $184.2m, margins remained above 30%, cash reserves stayed high while bank debt fell, and the interim dividend was raised by 11%, underscoring balance sheet strength and cash generation.
Operationally, the company accelerated innovation on its Trisus platform, including advanced AI developed with Microsoft and new functionality due to launch in the second half, and delivered the only fully integrated solution to address the evolving 340B rebate model before its pilot was postponed. Higher sales to new customers, strong net revenue retention at 103%, customer retention above 90% and an announced $25m share buyback support management’s confident outlook and signal ambitions to further strengthen its market position in U.S. healthcare finance technology.
The most recent analyst rating on (GB:CRW) stock is a Hold with a £1552.00 price target. To see the full list of analyst forecasts on Craneware stock, see the GB:CRW Stock Forecast page.
Spark’s Take on GB:CRW Stock
According to Spark, TipRanks’ AI Analyst, GB:CRW is a Neutral.
The score is driven primarily by solid financial performance (strong margins and a low-debt balance sheet), but it is meaningfully weighed down by weak technical momentum (price below key moving averages with negative MACD) and a relatively high P/E that limits valuation support despite the dividend yield.
To see Spark’s full report on GB:CRW stock, click here.
More about Craneware
Craneware plc is a U.K.-listed provider of healthcare financial performance solutions, focused on U.S. hospitals and health systems. Through its Trisus cloud ecosystem, the company offers revenue and margin intelligence, analytics and 340B drug programme tools that help providers optimise financial sustainability. A long-standing Microsoft partner, it leverages proprietary data and AI to support operational efficiency and regulatory change management.
Average Trading Volume: 171,842
Technical Sentiment Signal: Sell
Current Market Cap: £532.5M
For an in-depth examination of CRW stock, go to TipRanks’ Overview page.